For in vivo application toward metastasis treatment, the SEE platform was applied for remodeling AG cells from lung cancer patients by transfecting immunotherapy promoters, Interferon‐γ (IFN‐γ) plasmid, and Programmed cell death ligand 1(PD‐L1) siRNA. This evidence concerns the gene CD274 and lung carcinoma.